Heather E Tulloch1, Andrew L Pipe2, Matthew J Clyde3, Robert D Reid2, Charl Els4. 1. Division of Prevention and Rehabilitation, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; School of Psychology, University of Ottawa, Ottawa, Ontario, Canada;. Electronic address: hetulloch@ottawaheart.ca. 2. Division of Prevention and Rehabilitation, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. 3. Division of Prevention and Rehabilitation, University of Ottawa Heart Institute, Ottawa, Ontario, Canada; School of Psychology, University of Ottawa, Ottawa, Ontario, Canada. 4. Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada.
Abstract
INTRODUCTION: The purpose of this study is to better understand the quit experience and concerns of smokers with psychiatric illness (i.e., major depressive, anxiety, psychotic and bipolar disorders) in comparison with those without psychiatric illness. METHODS: Smokers (N=732) with (n=430, 59%) and without psychiatric illness, recruited between June 2010 and March 2013 to participate in the FLEX (Flexible and Extended Dosing of Nicotine Replacement Therapy [NRT] and Varenicline in Comparison to Fixed-Dose NRT for Smoking Cessation) smoking-cessation trial, completed questionnaires assessing previously used cessation aids and reasons for relapse, and motivation and concerns about their upcoming quit attempt. These supplementary data analyses were conducted in May 2015. RESULTS: The most commonly used cessation methods during previous attempts were nicotine replacement therapy (66.4%), cold turkey (59.7%), and bupropion (34.7%); no group differences were identified. Stress was the most common precipitator of relapse during previous attempts in all groups (43.6%), particularly among participants with depression and anxiety. Health was the most common motivation for the upcoming quit attempt (91%), followed by family/social pressures (28.1%) and cost (27.9%, particularly by smokers with psychotic disorders). Common pre-cessation concerns for the complete sample included: cravings (27.6%), stress (26.7%), and fear of failure (26%); participants with psychotic and anxiety disorders were most concerned about cravings, whereas the latter two concerns were more prominent for individuals with anxiety. CONCLUSIONS: Findings reveal differences in the quit histories and concerns of smokers with or without psychiatric illness. Smokers with psychiatric illness are particularly vulnerable to relapse at times of stress and negative affect; interventions that emphasize alternative coping strategies and facilitate mood management are required.
INTRODUCTION: The purpose of this study is to better understand the quit experience and concerns of smokers with psychiatric illness (i.e., major depressive, anxiety, psychotic and bipolar disorders) in comparison with those without psychiatric illness. METHODS: Smokers (N=732) with (n=430, 59%) and without psychiatric illness, recruited between June 2010 and March 2013 to participate in the FLEX (Flexible and Extended Dosing of Nicotine Replacement Therapy [NRT] and Varenicline in Comparison to Fixed-Dose NRT for Smoking Cessation) smoking-cessation trial, completed questionnaires assessing previously used cessation aids and reasons for relapse, and motivation and concerns about their upcoming quit attempt. These supplementary data analyses were conducted in May 2015. RESULTS: The most commonly used cessation methods during previous attempts were nicotine replacement therapy (66.4%), cold turkey (59.7%), and bupropion (34.7%); no group differences were identified. Stress was the most common precipitator of relapse during previous attempts in all groups (43.6%), particularly among participants with depression and anxiety. Health was the most common motivation for the upcoming quit attempt (91%), followed by family/social pressures (28.1%) and cost (27.9%, particularly by smokers with psychotic disorders). Common pre-cessation concerns for the complete sample included: cravings (27.6%), stress (26.7%), and fear of failure (26%); participants with psychotic and anxiety disorders were most concerned about cravings, whereas the latter two concerns were more prominent for individuals with anxiety. CONCLUSIONS: Findings reveal differences in the quit histories and concerns of smokers with or without psychiatric illness. Smokers with psychiatric illness are particularly vulnerable to relapse at times of stress and negative affect; interventions that emphasize alternative coping strategies and facilitate mood management are required.
Authors: A Eden Evins; Neal L Benowitz; Robert West; Cristina Russ; Thomas McRae; David Lawrence; Alok Krishen; Lisa St Aubin; Melissa Culhane Maravic; Robert M Anthenelli Journal: J Clin Psychopharmacol Date: 2019 Mar/Apr Impact factor: 3.153
Authors: Su Fen Lubitz; Alex Flitter; E Paul Wileyto; Douglas Ziedonis; Nathaniel Stevens; Frank Leone; David Mandell; John Kimberly; Rinad Beidas; Robert A Schnoll Journal: Nicotine Tob Res Date: 2020-08-24 Impact factor: 4.244
Authors: Dorothy A Rhoades; Ashley L Comiford; Justin D Dvorak; Kai Ding; Leslie M Driskill; Audrea M Hopkins; Paul Spicer; Theodore L Wagener; Mark P Doescher Journal: Am J Prev Med Date: 2019-08-01 Impact factor: 5.043
Authors: Assia Timila Touhouche; Benoit Chaput; Rose Marie Rouquet; Emilie Montastier; Philippe Caron; Yvon Gall; Christian Aquilina; Serge Boulinguez; Marie Claude Marguery; Françoise Giordano-Labadie; Juliette Mazereeuw; Carle Paul; Maria Polina Konstantinou Journal: Int J Womens Dermatol Date: 2020-02-22
Authors: Mackenzie Hosie Quinn; Matthew Olonoff; Anna-Marika Bauer; Erica Fox; Nancy Jao; Su Fen Lubitz; Frank Leone; Jacqueline K Gollan; Robert Schnoll; Brian Hitsman Journal: Nicotine Tob Res Date: 2022-01-01 Impact factor: 5.825